- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01096654
SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. (SPARTACUS)
Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan?
Rationale: Primary hyperaldosteronism (PA) is the most frequent form of secondary hypertension. In PA autonomous hypersecretion of aldosterone by one or both adrenal glands causes hypertension that is often refractory to treatment. PA is usually caused by either a unilateral aldosterone-producing (micro)adenoma (APA) or by bilateral adrenal hyperplasia (BAH). Distinction between APA and BAH is critical since the former is treated with the aim of cure by adrenalectomy, and the latter by mineralocorticoid receptor antagonists. This distinction can be made by adrenal vein sampling (AVS), as recommended by The Endocrine Society 2008 guideline or by CT-scanning, as is common practice in the Netherlands. AVS is invasive, demands great skill, and is expensive, while CT-scanning is non-invasive, easy and cheap, but might be less accurate. However, the advantage of AVS has never been demonstrated in prospective randomized studies. Here we propose to perform a prospective, randomized, multicenter study that compares effectiveness of AVS with effectiveness of CT-scanning for the diagnosis of PA subtype.
Objective: To assess the quantity of antihypertensive medication needed in order to normalize blood pressure in patients who have been managed for PA according to either AVS or CT-scan. Secondary objectives: to assess potassium, costs of management and quality of life.
Study design: Prospective, randomized trial in a multi-centre setting. Two hundred patients will be recruited within two years. Follow-up will be one year after (start of) treatment.
Study population: Adult patients with therapy-resistant hypertension, with or without hypokalemia, caused by PA.
Intervention: Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
Main study parameters/endpoints: The quantity of antihypertensive drugs patients are using to obtain target blood pressure, expressed in Daily Defined Dosages, is used as the main study parameter. There is no criterion standard for accuracy of the diagnosis of PA-subtype, but we assume that if treatment is based on a more accurate diagnosis, treatment is more effective. The most important secondary endpoints are the costs of the diagnostic course and long-term medical treatment and the quality of life as assessed by a validated questionnaire.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525 GA
- UMC St. Radboud
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Legally capacitated;
- ≥ 18 years of age;
- Diagnosed with hypertension that is difficult to treat (blood pressure > 140/90 mmHg in spite of two antihypertensive drugs in adequate doses), or accompanied by hypokalemia, either spontaneous or induced by use of diuretics;
- patients must have a positive result on a sodium loading test (as recommended in the Endocrine Society Guideline), i.e. insufficient suppression of aldosterone.
- Cooperating patient who is willing to undergo adrenal surgery in case of an adenoma or lateralized aldosterone secretion, who is able to comply with the study protocol and who is willing to give written informed consent.
Exclusion Criteria:
- Unsuitability for or objection to undergo AVS, CT or adrenal surgery.(including pregnancy);
- Glucocorticoid remediable aldosteronism or adrenal carcinoma;
- Severe or terminal co-morbidity which seriously interferes with possible treatment or health related quality of life;
- Requirement of certain medication that interacts with the prescribed treatments in this protocol or that can cause hypertension as an important side-effect e.g. glucocorticoids. Patients will only be excluded as the medication cannot be stopped or altered.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CT-scan
In this group treatment will be based on the outcome of the CT-scan only.
Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal.
If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
|
Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography).
The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
|
Active Comparator: Adrenal Vein Sampling
This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava. If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA. |
Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography).
The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Defined Doses of antihypertensive medication
Time Frame: assessed after 1 year of follow-up
|
The main study parameter is the quantity of antihypertensive drugs patients are using to obtain target blood pressure, expressed in Daily Defined Doses (DDD)16.
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults.
It provides a fixed unit of measurement independent of price and dosage form (e.g.
tablet strength) enabling the researcher to assess trends in drug consumption and to perform comparisons between population groups.
|
assessed after 1 year of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total cost of diagnosis and management
Time Frame: assessed after 1 year follow-up
|
Costs of the diagnostic course and the first year of treatment after determination of subtype of PA will be calculated prospectively and bottom-up for each participant.
This includes costs of CT, AVS (hardware, rent of facility, lab determinations, cost of personnel), operation, outpatient clinic visits, medication and lab controls for potassium and creatinine.
Long term costs will be extrapolated from the first year's results for an average life expectancy and a predefined discounting rate.
|
assessed after 1 year follow-up
|
Health Related Quality of Life
Time Frame: assesed before treatment, at 6 months and at 12 months follow-up
|
The quality of life in our patients may be influenced in different ways.
AVS is more invasive and more burdensome to the patient than CT; the same holds for surgery as compared to medical treatment; on the other hand, more intense and prolonged (lifelong) antihypertensive drug treatment may be associated with more side effects.
We suggested to explore these issues, using the .
EQ-5D (European Quality of Life-5 Dimensions) and the SF-36 (Medical Outcomes Study 36-Item Short-Form Health Survey).
This will allow for a detailed analysis of the impact of the two strategies on the quality of life of the patients.
|
assesed before treatment, at 6 months and at 12 months follow-up
|
Potassium level
Time Frame: assesed before treatment and after 1 year follow-up
|
Serum potassium levels will be determined before Adx or start of MRA and one year later.
Potassium levels will be compared between the two arms of the study.
|
assesed before treatment and after 1 year follow-up
|
Result of a sodium loading test
Time Frame: assessed after 1 year follow-up
|
This test, which is the reference test for the existence of PA, will be performed only in patients that have undergone adrenalectomy because in these patients PA is expected to be cured after adrenalectomy with hence a normal result of this test.
The test will be performed 1 year after operation after interruption of medication that interferes with the measurement of aldosterone levels.
The proportion of patients who were cured (i.e. with normal saline loading test) will be compared between the CT- and the AVS-group.
|
assessed after 1 year follow-up
|
Post-hoc analysis: medication dosage
Time Frame: assessed after 1 year follow-up
|
A post-hoc analysis on medication use will be performed using different outcome measures.
Required antihypertensive medication one year after the (start of) treatment, expressed in multiples of the recommended starting dose and fraction of the recommended maximum dose, will be analysed.
|
assessed after 1 year follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jacob Deinum, Dr., UCM St. Radboud
Publications and helpful links
General Publications
- Stewart PM, Allolio B. Adrenal vein sampling for Primary Aldosteronism: time for a reality check. Clin Endocrinol (Oxf). 2010 Feb;72(2):146-8. doi: 10.1111/j.1365-2265.2009.03714.x. Epub 2009 Sep 21. No abstract available.
- Mulatero P, Bertello C, Sukor N, Gordon R, Rossato D, Daunt N, Leggett D, Mengozzi G, Veglio F, Stowasser M. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension. 2010 Mar;55(3):667-73. doi: 10.1161/HYPERTENSIONAHA.109.146613. Epub 2010 Feb 1.
- Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009 Sep 1;151(5):329-37. doi: 10.7326/0003-4819-151-5-200909010-00007.
- Kline GA, Harvey A, Jones C, Hill MH, So B, Scott-Douglas N, Pasieka JL. Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used. Variable interpretation of adrenal vein sampling. Int Urol Nephrol. 2008;40(4):1035-43. doi: 10.1007/s11255-008-9441-9. Epub 2008 Aug 12.
- Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, Schultze Kool L, Langenhuijsen J, Prejbisz A, van der Wilt GJ, Deinum J; SPARTACUS investigators. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab. 2018 Jan 1;103(1):16-24. doi: 10.1210/jc.2017-01442.
- Dekkers T, Prejbisz A, Kool LJS, Groenewoud HJMM, Velema M, Spiering W, Kolodziejczyk-Kruk S, Arntz M, Kadziela J, Langenhuijsen JF, Kerstens MN, van den Meiracker AH, van den Born BJ, Sweep FCGJ, Hermus ARMM, Januszewicz A, Ligthart-Naber AF, Makai P, van der Wilt GJ, Lenders JWM, Deinum J; SPARTACUS Investigators. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016 Sep;4(9):739-746. doi: 10.1016/S2213-8587(16)30100-0. Epub 2016 Jun 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Adrenocortical Hyperfunction
- Adrenal Gland Diseases
- Hyperaldosteronism
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Epinephrine
- Racepinephrine
- Epinephryl borate
Other Study ID Numbers
- avs-ct1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperaldosteronism
-
Haukeland University HospitalCompleted
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPrimary Hyperaldosteronism | Electrolyte DisturbanceGermany
-
University Hospital, CaenRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy | Essential Hypertension | Primary Hyperaldosteronism | Secondary HyperaldosteronismFrance
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
NovartisCompletedPrimary HyperaldosteronismFrance
-
University College, LondonUniversity College London Hospitals; Cambridge University Hospitals NHS Foundation... and other collaboratorsCompletedPrimary Hyperaldosteronism | Primary Hyperaldosteronism Due to Adrenal AdenomaUnited Kingdom
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingPrimary Aldosteronism | Aldosterone-Producing Adenoma | Idiopathic HyperaldosteronismChina
-
Imperial College LondonDr Katrina Ohla, Institute of Neuroscience and Medicine, Julich, GermanyUnknownHypertension | Hyperaldosteronism; Primary | Salt; Excess | Appetite DisordersUnited Kingdom
-
Radboud University Medical CenterCompletedPrimary HyperaldosteronismNetherlands
Clinical Trials on Ct-scan or adrenal vein sampling
-
Medical University InnsbruckRuth Kröss, MD EDAIC; Glodny Bernhard, MD PD Assoc. Prof.; Laura Trefzer, Cand... and other collaboratorsCompletedEmergencies | Bone Infection | Infusion Site InjuryAustria
-
Instituto de Investigacion Sanitaria La FeCharite University, Berlin, Germany; Imperial College London; Instituto de Investigación... and other collaboratorsRecruitingGynecologic Cancer | Anastomotic Leak | Cytoreductive SurgerySpain
-
Yale UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
Assistance Publique - Hôpitaux de ParisEuropean UnionUnknownCardiometabolic DiseaseDenmark, France, Germany
-
Emory UniversityBlue Earth Diagnostics; Nihon Medi-Physics Co., Ltd.Completed
-
Rambam Health Care CampusCompletedClassical Hodgkin Lymphoma | Nodular Sclerosis | Mixed Cellularity | Lymphocyte Depletion | Lymphocyte RichIsrael
-
LMU KlinikumRecruitingAnkle Fractures | Proximal Humeral Fracture | Distal Radius FracturesGermany
-
Medhat OsmanBlue Earth DiagnosticsCompleted
-
Angle plcMedical University of Vienna; Charite University, Berlin, Germany; Vivantes Netzwerk...CompletedEvaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.Ovarian NeoplasmsGermany, Austria
-
The Christie NHS Foundation TrustRecruiting